Key points are not available for this paper at this time.
Abstract PURPOSE: To describe the implementation process of the CCP and demonstrate their impact in terms of ERV and NIA. METHODS: The CCP was designed as a remote web-based where patients could find information about their diagnosis, treatment and adverse symptoms. An e-PRO questionnaire was developed. The impact was examined for: ERV and NIA through a cohort analysis of patients with gastrointestinal (GI) cancer receiving systemic treatment at Oncosalud-AUNA between June 2021- July 2022. The cohorts were: 1) patients who enrolled into the CCP and 2) otherwise eligible patients not enrolled into CCP. Incidence rate (IR), IR ratios (IRR) and 95% confidence intervals were calculated. Time to first ERV and NIA curves were constructed using the Kaplan Meier method and log rank test. RESULTS: 199 participants, 97 enrolled into CCP. Median age was 61 years (30 - 92 years). 51.5% of patients was EGOG 0-1. Chemotherapy was the most common treatment (88.4%). The mean follow time was of 8.3 and 6.7 months, for patients in CCP and not, respectively. ERV IR was 15.1 per month for patients enrolled into the CCP (95%CI: 12.6-18.0) vs. 20.3 per month for patients not enrolled (95% CI: 17.0-24.0) which translated into a 25% decrease in ERV (IRR: 0.75 (95%CI: 0.58-0.96; p=0.02)). NIA IR was 5.9 per month for patients enrolled into the CCP (95%CI: 4.4-7.8) vs. 9.2 per month for patients not enrolled (95%CI: 7.0-11.8) which translated into a 35% decrease in NIA (IRR: 0.65 (95%CI: 0.44-0.96; p=0.02)). CONCLUSIONS: Our study demonstrates the feasibility of the CCP in our reality and the impact that it has reducing the utilization of other healthcare services.
Rioja et al. (Tue,) studied this question.